You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
NORTHBROOK, Ill., May 19, 2016 /PRNewswire/ -- Astellas announced today a selection of abstracts it will present on early phase data for ASP8273 in patients with EGFR mutation positive non-small cell lung cancer (NCSLC), gilteritinib pharmacokinetics and pharmacodynamics in patients with relapsed or refractory acute myeloid leukemia and two investigational antibody drug conjugates in patients with metastatic urothelial cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 in Chicago.
"Our activity at this year's ASCO annual meeting underscores our immense commitment to helping those living with cancer," said Stephen Eck, M.D., vice president and interim head of global oncology development, Astellas. "Building on our foundation in non-small cell lung, pancreatic and advanced prostate cancers, we are continuously focused on identifying innovative ways to address the unmet needs of patients and caregivers facing cancer every day."
The following are a selection of abstracts that will be presented during poster sessions:
Title: (9050) Antitumor Activity of ASP8273 300mg in Subjects with EGFR Mutation-Positive Non-Small Cell Lung Cancer: Interim Results from an Ongoing Phase 1 Study.
Presenter: Helena Alexandra Yu, M.D., Memorial Sloan Kettering Cancer Center
Title: (7026) Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.
Presenter: Catherine Choy Smith, M.D., University of California San Francisco
Title: (4532) Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of AGS15E (ASG-15ME) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC)
Presenter: Daniel Peter Petrylak, M.D., Yale University
Title: (4533) Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC)
Presenter: Jonathan E. Rosenberg, M.D., Memorial Sloan Kettering Cancer Center
AGS15E and ASG-22CE are being co-developed under a collaboration with Seattle Genetics.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
SOURCE Astellas Pharma Inc.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.